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Abstract
Background: Upfront cytoreductive surgery with HIPEC (CRS-HIPEC) is the standard treatment for isolated
resectable colorectal peritoneal metastases (PM) in the Netherlands. This study investigates whether addition of
perioperative systemic therapy to CRS-HIPEC improves oncological outcomes.
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Methods: This open-label, parallel-group, phase II-III, randomised, superiority study is performed in nine Dutch
tertiary referral centres. Eligible patients are adults who have a good performance status, histologically or
cytologically proven resectable PM of a colorectal adenocarcinoma, no systemic colorectal metastases, no systemic
therapy for colorectal cancer within six months prior to enrolment, and no previous CRS-HIPEC. Eligible patients are
randomised (1:1) to perioperative systemic therapy and CRS-HIPEC (experimental arm) or upfront CRS-HIPEC alone
(control arm) by using central randomisation software with minimisation stratified by a peritoneal cancer index of
0–10 or 11–20, metachronous or synchronous PM, previous systemic therapy for colorectal cancer, and HIPEC with
oxaliplatin or mitomycin C. At the treating physician’s discretion, perioperative systemic therapy consists of either
four 3-weekly neoadjuvant and adjuvant cycles of capecitabine with oxaliplatin (CAPOX), six 2-weekly neoadjuvant
and adjuvant cycles of 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX), or six 2-weekly neoadjuvant cycles of 5-
fluorouracil/leucovorin with irinotecan (FOLFIRI) followed by four 3-weekly (capecitabine) or six 2-weekly (5-fluorouracil/
leucovorin) adjuvant cycles of fluoropyrimidine monotherapy. Bevacizumab is added to the first three (CAPOX) or four
(FOLFOX/FOLFIRI) neoadjuvant cycles. The first 80 patients are enrolled in a phase II study to explore the feasibility of
accrual and the feasibility, safety, and tolerance of perioperative systemic therapy. If predefined criteria of feasibility and
safety are met, the study continues as a phase III study with 3-year overall survival as primary endpoint. A total of 358
patients is needed to detect the hypothesised 15% increase in 3-year overall survival (control arm 50%; experimental
arm 65%). Secondary endpoints are surgical characteristics, major postoperative morbidity, progression-free survival,
disease-free survival, health-related quality of life, costs, major systemic therapy related toxicity, and objective
radiological and histopathological response rates.
Discussion: This is the first randomised study that prospectively compares oncological outcomes of perioperative
systemic therapy and CRS-HIPEC with upfront CRS-HIPEC alone for isolated resectable colorectal PM.
Trial registration: Clinicaltrials.gov/NCT02758951, NTR/NTR6301, ISRCTN/ISRCTN15977568, EudraCT/2016–001865-99.
Keywords: Colorectal neoplasms, Peritoneal neoplasms, Cytoreduction surgical procedures, Hyperthermia, induced,
Neoadjuvant therapy, Adjuvant chemotherapy, Bevacizumab, Randomized controlled trial, Mortality, Progression-free
survival
Background
The peritoneum is the second most common isolated
metastatic site of colorectal cancer after the liver [1, 2]. Pa-
tients with isolated colorectal peritoneal metastases (PM)
have a poor median survival, ranging from several months
to approximately one year [2–6]. In the Netherlands, nearly
30 % of these patients undergo cytoreductive surgery with
hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
[6]. Median survival in this selected group approaches
three years with a small chance of cure [7, 8]. The increas-
ing acceptance of CRS-HIPEC in clinical practice is sup-
ported by a randomised study and several observational
series [7, 9–11]. In the Netherlands, upfront CRS-HIPEC is
the current standard treatment for isolated resectable colo-
rectal PM [12]. The addition of neoadjuvant and adjuvant
systemic therapy, together commonly referred to as peri-
operative systemic therapy, to CRS-HIPEC has potential
benefits and drawbacks.
Potential benefits of perioperative systemic therapy
Perioperative systemic therapy may eradicate systemic
micrometastases. Colorectal PM mostly arise from ad-
vanced primary tumours with a high risk of systemic
spread [1, 3, 4]. Indeed, systemic failure is common after
CRS-HIPEC [13]. Moreover, lymph node positivity is as-
sociated with poor outcomes after CRS-HIPEC [14],
probably due to higher systemic recurrence rates. Peri-
operative systemic therapy could improve outcomes by
decreasing the risk of systemic failure.
Secondly, neoadjuvant systemic therapy may decrease
the intraperitoneal tumour load. Objective morphological
and histopathological responses to neoadjuvant systemic
therapy are reported in about 50 and 30% of patients with
colorectal PM, respectively [15, 16]. Patients with response
could have favourable outcomes due to a lower intraoper-
ative disease load, a higher chance of a complete cytore-
duction, and less extensive surgery potentially leading to a
lower postoperative morbidity [17, 18].
Thirdly, adjuvant systemic therapy may eradicate re-
sidual cancer cells after CRS-HIPEC. This could improve
oncological outcomes by decreasing recurrence rates, as
suggested by studies focusing on non-peritoneal colorec-
tal metastases [19].
Lastly, response assessment to neoadjuvant systemic
therapy could improve patient selection for CRS-HIPEC.
Potentially harmful CRS-HIPEC may be avoided in pa-
tients with early progression who are unlikely to benefit
due to an unfavourable tumour biology, whereas patients
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with a favourable response could achieve relevant long-
term survival [20, 21].
Potential drawbacks of perioperative systemic therapy
Systemic therapy appears to be less effective for colorec-
tal PM compared to non-peritoneal colorectal metasta-
ses [22]. This phenomenon may be explained by relative
insensitivity of PM to systemic treatment [23], probably
as a result of a low intraperitoneal concentration of sys-
temically administered drugs [24]. Thereby, preoperative
disease progression and secondary unresectability could
occur in a substantial number of patients who receive
neoadjuvant systemic therapy [25, 26].
Secondly, perioperative administration of systemic
therapy may decrease its reintroduction rate at disease
recurrence, which occurs in the vast majority of patients
[8]. As a result, perioperative systemic therapy probably
only prolongs the progression-free interval without im-
proving overall survival, as previously observed for re-
sectable colorectal liver metastases [27, 28].
Thirdly, systemic therapy is associated with toxicity [29].
Some patients could become ineligible for CRS-HIPEC
due to systemic therapy related toxicity. Moreover, pre-
operative administration of bevacizumab may increase
postoperative complications after CRS-HIPEC [30]. Peri-
operative systemic therapy and its toxicity intensify and
prolong the initial treatment period, which could interfere
with qualify of life.
Lastly, perioperative systemic therapy and its toxicity
could increase health care costs, especially in the era of
increasing use of targeted agents [31, 32].
Rationale for this study
For isolated resectable colorectal PM, there are no rando-
mised studies that prospectively compare the oncological
efficacy of perioperative systemic therapy and CRS-HIPEC
with upfront CRS-HIPEC alone [33]. The available evi-
dence solely consists of clinically heterogeneous, often
non-consecutive observational studies with high risks of
selection bias [33]. Notwithstanding the lack of evidence,
perioperative systemic therapy is widely administered to
patients with isolated resectable colorectal PM [33]. How-
ever, administration and timing of perioperative systemic
therapy vary substantially between countries, hospitals,
and guidelines [9, 33–35]. More importantly, it remains
unknown whether perioperative systemic therapy has an
intention-to-treat benefit in this setting [33–35]. There-
fore, this study randomises patients with isolated resect-
able colorectal PM to receive either perioperative systemic
therapy and CRS-HIPEC or upfront CRS-HIPEC alone.
Rationale for perioperative systemic regimen
A total period of six months of perioperative systemic
therapy is divided into three months of neoadjuvant
systemic therapy and three months of adjuvant systemic
therapy. A partially preoperative administration of sys-
temic therapy could be beneficial, since some patients are
unable to receive adjuvant systemic therapy due to post-
operative morbidity [36]. Moreover, systemic therapy may
be better tolerated before than after CRS-HIPEC, hence
allowing increased dose-intensity. The potential advan-
tages of a preoperative strategy have already been demon-
strated in patients with other resectable gastrointestinal
malignancies [37–39].
The rationale for the neoadjuvant regimen is derived
from first-line studies in metastatic colorectal cancer.
Doublet chemotherapy consisting of a fluoropyrimidine
with either oxaliplatin or irinotecan achieves higher re-
sponse rates than fluoropyrimidine monotherapy [40–43].
Combinations of 5-fluorouracil/leucovorin with oxaliplatin
(FOLFOX), capecitabine with oxaliplatin (CAPOX),
5-fluorouracil/leucovorin with irinotecan (FOLFIRI), and
capecitabine with irinotecan (CAPIRI) have a similar effi-
cacy [44], but the latter has an unfavourable toxicity profile
[45–47]. Although triplet chemotherapy achieves higher re-
sponse rates than doublet chemotherapy, it substantially in-
creases toxicity [48]. Doublet chemotherapy may therefore
be preferable, since patients in this study have resectable
disease without a need for aggressive conversion therapy.
The efficacy of doublet chemotherapy is increased by the
addition of epidermal growth factor (EGFR) inhibitors or
bevacizumab [49, 50]. When added to doublet chemother-
apy, similar response rates are observed for EGFR inhibitors
and bevacizumab [51–53]. However, unexpectedly un-
favourable outcomes were observed after addition of the
EGFR inhibitor cetuximab to perioperative doublet chemo-
therapy for resectable colorectal liver metastases [54].
Therefore, bevacizumab seems to be the preferred targeted
agent, as suggested by some observational and experimen-
tal studies focusing on colorectal PM [16, 55, 56]. It is not
beneficial to add EGFR inhibitors to doublet chemotherapy
with bevacizumab [57, 58]. Taken together, neoadjuvant
systemic therapy in this study comprises bevacizumab with
either CAPOX, FOLFOX, or FOLFIRI.
The rationale for the adjuvant regimen is derived from
adjuvant studies in high-risk colon cancer. Fluoropyrimidine
monotherapy is more effective than observation [59, 60],
with a similar efficacy of capecitabine and 5-fluorouracil/
leucovorin [61]. Addition of oxaliplatin to fluoropyrimidines
is beneficial [62–64], while addition of irinotecan is not
[65–68]. It is not beneficial to add targeted therapies to ad-
juvant chemotherapy [69–73]. Conclusively, adjuvant sys-
temic therapy in this study consists of either CAPOX,
FOLFOX, or fluoropyrimidine monotherapy.
Rationale for phase II-III approach
This is the first prospective multicentre study in patients
with isolated resectable colorectal PM in the Netherlands.
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Moreover, perioperative chemotherapy with bevacizumab
has never been prospectively investigated in this particular
patient population. As a result, little is known about the
feasibility of conducting such a study and about the feasi-
bility, safety, and tolerance of perioperative chemotherapy
with bevacizumab in this setting. These issues are carefully
assessed by incorporation of a randomised phase II (pilot)
study, as previously successfully performed in the FOx-
TROT study on preoperative chemotherapy for locally ad-
vanced resectable colon cancer [74].
Methods
This protocol summary follows the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) Statement [75].
Study design
This is a multicentre, open-label, parallel-group, phase
II-III, superiority study that randomises eligible patients
in a 1:1 ratio to receive either perioperative systemic
therapy and CRS-HIPEC (experimental arm) or upfront
CRS-HIPEC alone (control arm).
Objectives
Objectives of the phase II study are to explore the feasi-
bility of accrual, the feasibility, safety, and tolerance of
perioperative systemic therapy, and the radiological and
histopathological response of colorectal PM to neoadju-
vant systemic therapy.
The primary objective of the phase III study is to com-
pare survival outcomes between both arms. Secondary
objectives are to compare surgical characteristics, major
postoperative morbidity, health-related quality of life,
and costs between both arms. Secondary objectives con-
fined to the experimental arm are to assess major sys-
temic therapy related toxicity and the objective
radiological and histopathological response of colorectal
PM to neoadjuvant systemic therapy.
Study setting
In the phase II study, accrual, perioperative systemic
therapy, and CRS-HIPEC are restricted to nine study
centres. These study centres include all Dutch tertiary
referral centres qualified for the surgical treatment of
colorectal PM, consisting of five university hospitals and
four teaching hospitals.
In the subsequent phase III study, accrual and
CRS-HIPEC remain restricted to the nine study centres,
whereas perioperative systemic therapy can be adminis-
tered in about fifteen additional satellite centres. These
satellite centres are Dutch university and (non-)teaching
hospitals qualified for the systemic treatment of patients
with metastatic colorectal cancer. A list of study sites
can be obtained at ClinicalTrials.gov (NCT02758951).
Eligibility criteria
Patients
Eligible patients are adults who have a World Health Or-
ganisation (WHO) performance status of ≤1, histological
or cytological proof of PM of a non-appendiceal colorec-
tal adenocarcinoma with ≤50% of the tumour cells being
signet ring cells, resectable disease determined by
abdominal computed tomography (CT) and a diagnostic
laparoscopy/laparotomy, no evidence of systemic colo-
rectal metastases within three months prior to enrol-
ment, no systemic therapy for colorectal cancer within
six months prior to enrolment, no contraindications for
CRS-HIPEC, no previous CRS-HIPEC, and no concur-
rent malignancies that interfere with the planned study
treatment or the prognosis of resected colorectal PM.
Enrolled patients need to be discussed in a multidiscip-
linary team meeting in a study centre prior to enrol-
ment. Importantly, enrolment is allowed for patients
with radiologically non-measurable disease. The diag-
nostic laparoscopy/laparotomy may be performed in a
referring centre, provided that the peritoneal cancer
index (PCI) is appropriately scored and documented be-
fore enrolment [76].
Patients are excluded in case of any comorbidity or
condition that prevents safe administration of the
planned perioperative systemic therapy, determined by
the treating medical oncologist (e.g. inadequate bone
marrow, renal, or liver functions, previous intolerance of
fluoropyrimidines or both oxaliplatin and irinotecan,
dehydropyrimidine dehydrogenase deficiency, recent
major cardiovascular events, bleeding diathesis, pregnant
or lactating women).
Participating centres
Study centres should be qualified as tertiary referral cen-
tres for the surgical treatment of colorectal PM, with at
least 20 procedures of CRS-HIPEC each year. Satellite
centres should be qualified for the systemic treatment of
patients with metastatic colorectal cancer.
Interventions and procedures
Figure 1 shows a general flowchart of the study. Tables 1
and 2 present schedules of enrolment, interventions, and
assessments of the experimental arm and the control
arm, respectively.
Perioperative systemic therapy
Figure 2 shows a flowchart of the perioperative systemic
therapy in the experimental arm. At the discretion of the
treating medical oncologist, perioperative systemic ther-
apy consists of either:
 Four three-weekly neoadjuvant and adjuvant cycles of
CAPOX (130mg/m2 body-surface area [BSA] of
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oxaliplatin, intravenously [IV] on day 1; 1000mg/m2
BSA of capecitabine, orally twice daily on days 1–14),
with bevacizumab (7.5mg/kg body weight, IV on day
1) added to the first three neoadjuvant cycles, or;
 Six two-weekly neoadjuvant and adjuvant cycles of
FOLFOX (85 mg/m2 BSA of oxaliplatin, IV on day 1;
400 mg/m2 BSA of leucovorin, IV on day 1; 400/
2400 mg/m2 BSA of bolus/continuous 5-fluorouracil,
IV on day 1/1–2), with bevacizumab (5 mg/kg body
weight, IV on day 1) added to the first four neoadju-
vant cycles, or;
 Six two-weekly neoadjuvant cycles of FOLFIRI (180
mg/m2 BSA of irinotecan, IV on day 1; 400 mg/m2
BSA of leucovorin, IV on day 1; 400/2400 mg/m2
BSA of bolus/continuous 5-fluorouracil, IV on day
1/1–2) and either four three-weekly (capecitabine
(1000 mg/m2 BSA, orally twice daily on days 1–14)
or six two-weekly (400 mg/m2 BSA of leucovorin, IV
on day 1; 400/2400 mg/m2 BSA of bolus/continuous
5-fluorouracil, IV on day 1/1–2) adjuvant cycles of
fluoropyrimidine monotherapy, with bevacizumab
(5 mg/kg body weight, IV on day 1) added to the
first four neoadjuvant cycles.
Neoadjuvant systemic therapy should start within four
weeks after randomisation. Adjuvant systemic therapy
should start within twelve weeks after CRS-HIPEC. In
case of unacceptable toxicity or contraindications to
oxaliplatin or irinotecan in the neoadjuvant setting,
CAPOX or FOLFOX may be switched to FOLFIRI and
vice versa. In case of unacceptable toxicity or contraindi-
cations to oxaliplatin in the adjuvant setting, CAPOX of
FOLFOX may be switched to fluoropyrimidine mono-
therapy. Dose reduction, prohibited concomitant care,
permitted concomitant care, and strategies to improve
adherence are not specified a priori, but left to the dis-
cretion of the treating medical oncologist. Perioperative
systemic therapy can be prematurely discontinued due
to radiological or clinical disease progression, unaccept-
able toxicity, physicians decision, or at patients request.
CRS-HIPEC
CRS-HIPEC is performed according to the Dutch protocol
in all study centres [77]. The choice of HIPEC medication
(oxaliplatin or mitomycin C) is left to the discretion of the
treating physician, since neither one has a favourable
safety or efficacy [78, 79]. In the control arm, CRS-HIPEC
should be performed within six weeks after randomisa-
tion. In the experimental arm, CRS-HIPEC should be per-
formed within six weeks after completion of neoadjuvant
systemic therapy, and at least six weeks after the
last administration of bevacizumab to minimise the
risk of bevacizumab-related postoperative complica-
tions [80].
Fig. 1 General flowchart of the CAIRO6 study. B blood for translational research; CRS-HIPEC cytoreductive surgery with hyperthermic intraperitoneal
chemotherapy; CT thoracoabdominal computed tomography; Q questionnaires (EQ-5D-5L, QLQ-C30, QLQ-CR29, iMTA Productivity Cost Questionnaire,
iMTA Medical Consumption Questionnaire); T tissue for translational research
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Follow-up
In the control arm, thoracoabdominal CT is performed
three, six, and twelve months after CRS-HIPEC, and every
six months thereafter until five years after randomisation.
In the experimental arm, thoracoabdominal CT is per-
formed three and nine months after CRS-HIPEC, and every
six months thereafter until five years after randomisation.
This follow-up schedule allows for an equal comparison of
progression-free survival between both arms (Fig. 1).
Questionnaires
EQ-5D-5L [81, 82], QLQ-C30 [83], QLQ-CR29 [84],
iMTA productivity cost questionnaire (PCQ) [85], and
iMTA medical consumption questionnaire (MCQ) [86]
are sent to the patients before study treatment, after
completion of neoadjuvant systemic therapy (experimen-
tal arm), every three months after CRS-HIPEC until one
year postoperatively, and every six months thereafter
until five years after randomisation (Fig. 1).
Translational research – blood
An additional 20 ml blood is drawn and collected in
10 ml Cell-free DNA BCT tubes (Streck, La Vista,
NE, USA) during regular blood draws before study
treatment, between the first and the second cycle of
neoadjuvant systemic therapy (experimental arm), one
Table 1 Schedule of enrolment, interventions, and assessments of the experimental arm
Study period
Enrolment/
allocation
Post-allocation Close-out
Outpatient
clinics
Neoadjuvant
treatment
CRS-
HIPEC
Adjuvant
treatment
3 months after
CRS-HIPEC
6months after
CRS-HIPEC
9 months after
CRS-HIPEC
Every 6
months
5 years after
randomisation
Enrolment/allocation
Eligibility screen X
Informed consent X
Allocation X
Interventions
Chemotherapy X X
Bevacizumab Xa
CRS-HIPEC X
Thoracoabdominal CT Xb X X X X
Questionnaires X Xc X X X X X
Translational research: blood X Xd Xe Xd X X X X
Translational research: tissue X
Assessments
Baseline characteristics X
Feasibility of systemic therapy X X X
Safety/toxicity of systemic therapy X X X
Radiological response X
Histopathological response X
Surgical characteristics X
Postoperative morbidity X X
Progression-free survival X X X X X X X X
Disease-free survival X X X X X X X
Overall survival X X X X X X X X
Health-related quality of life X X X X X X X X
Costs X X X X X X X X
CRS-HIPEC cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, CT computed tomography
aAdded to the first three (CAPOX) or four (FOLFOX/FOLFIRI) cycles of neoadjuvant chemotherapy
bAfter three (CAPOX with bevacizumab) or four (FOLFOX/FOLFIRI with bevacizumab) cycles
cAfter completion of neoadjuvant systemic therapy, before CRS-HIPEC
dBetween the first and the second cycle of (neo)adjuvant systemic therapy
e1 day before CRS-HIPEC and 7 days after CRS-HIPEC
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day before CRS-HIPEC, seven days after CRS-HIPEC,
between the first and the second cycle of adjuvant
systemic therapy (experimental arm), and every
follow-up visit until disease recurrence or five years
after randomisation (Fig. 1). According to the manu-
facturer’s instructions, collected specimens are sent to
a central lab, where plasma and cell pellet are isolated
and stored at − 80 °C.
Translational research – tissue
In all patients undergoing CRS-HIPEC, tissue speci-
mens of colorectal PM and the primary tumour are
systematically collected and stored for translational
research in the study centres. Three resected colorec-
tal PM, preferably from different regions, are col-
lected separately. When resected, three regions of up
to ±1.5 cm3 are excised from the primary tumour.
Tumour tissue of each metastasis and each region of
the primary tumour is stored as both formalin-fixed
paraffin-embedded tissue and fresh frozen tissue at −
80 °C. Lastly, a piece of normal tissue is collected and
stored as fresh frozen tissue at − 80 °C.
Outcomes
Outcomes of the phase II study are to explore
 the feasibility of accrual, based on the total accrual
rate, the accrual rate in each study centre, screening
logs, and screening failures;
 the feasibility of perioperative systemic therapy,
based on the number of patients that (1) start and
complete neoadjuvant systemic therapy, with or
without dose reductions, (2) are scheduled for CRS-
HIPEC, (3) undergo complete CRS-HIPEC, and (4)
start and complete adjuvant systemic therapy, with
or without dose reductions;
 the safety of perioperative systemic therapy, based
on the number of patients with (1) systemic therapy
related toxicity, defined as grade ≥ 2 according to the
Common Terminology Criteria for Adverse Events
(CTCAE) v4.0 [87], up to one month after the last
administration of systemic therapy, and (2)
postoperative morbidity, defined as grade ≥ 2
according to Clavien-Dindo [88], up to three months
after CRS-HIPEC;
Table 2 Schedule of enrolment, interventions, and assessments of the control arm
Study period
Enrolment/
allocation
Post-allocation Close-out
Outpatient
clinics
CRS-HIPEC 3months after
CRS-HIPEC
6months after
CRS-HIPEC
9 months after
CRS-HIPEC
12 months after
CRS-HIPEC
Every 6
months
5 years after
randomisation
Enrolment/allocation
Eligibility screen X
Informed consent X
Allocation X
Interventions
CRS-HIPEC X
Thoracoabdominal CT X X X X X
Questionnaires X X X X X X X
Translational research: blood X Xa X X X X X
Translational research: tissue X
Assessments
Baseline characteristics X
Surgical characteristics X
Postoperative morbidity X X
Progression-free survival X X X X X X X
Disease-free survival X X X X X X X
Overall survival X X X X X X X
Health-related quality of life X X X X X X X X
Costs X X X X X X X X
a1 day before CRS-HIPEC and 7 days after CRS-HIPEC; CRS-HIPEC cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, CT computed tomography
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 the tolerance of perioperative systemic therapy,
based on health-related quality of life extracted from
EQ-5D-5 L, QLQ-C30, and QLQ-CR29 during study
treatment;
 the radiological and histopathological response of
colorectal PM to neoadjuvant systemic therapy,
based on central review of thoracoabdominal CT
and resected specimens, respectively. Classifications
are not defined a priori.
The primary outcome of the phase III study is
3-year overall survival, defined as the number of pa-
tients who are alive three years after randomisation.
Secondary outcomes in both arms are:
 progression-free survival, defined as the time
between randomisation and disease progression
before CRS-HIPEC, CRS-HIPEC in case of
unresectable disease, radiological proof of
recurrence, or death;
 disease-free survival, defined as the time between CRS-
HIPEC and radiological proof of recurrence or death;
 health-related quality of life, extracted from
questionnaires (EQ-5D-5L, QLQ-C30, QLQ-CR29)
at different points in time (Fig. 1, Tables 1 & 2);
 costs, derived from the Dutch costing guidelines
for health care research at the time of analysis,
based on case report forms, hospital information
systems, and questionnaires (iMTA PCQ, iMTA
MCQ, EQ-5D-5L) at different points in time
(Fig. 1, Tables 1 & 2) [82];
 surgical characteristics of CRS-HIPEC
(e.g. intraoperative complications, operating time,
visceral and peritoneal resections, completeness of
cytoreduction);
 the number of patients with major postoperative
morbidity, defined as grade ≥ 3 according to Clavien-
Dindo, up to three months after CRS-HIPEC.
Secondary outcomes confined to the experimental arm
are:
 the number of patients with major systemic therapy
related toxicity, defined as grade ≥ 3 according to the
CTCAE, up to one month after the last
administration of systemic therapy;
 the number of patients with an objective radiological
and histopathological response of colorectal PM to
neoadjuvant systemic therapy, determined by central
review of thoracoabdominal CT and resected
specimens, respectively. Classifications are
determined after exploration of the radiological and
histopathological response in the phase II study.
Sample size
The sample size of 80 (40 in each arm) for the phase
II study is chosen pragmatically as a sufficient number
to explore the feasibility of accrual and the feasibility,
safety, and tolerance of perioperative systemic therapy.
The sample size calculation of the phase III study
could only be based on a combination of low-quality
observational studies [15, 16, 20, 21, 36, 57, 89–91]. A
total number of 358 patients (179 in each arm) is
needed to detect the hypothesised 15% increase in
3-year overall survival (control arm 50%; experimental
arm 65%) with 5% drop-out, 80% power, and a
Fig. 2 Flowchart of the perioperative systemic therapy in the experimental arm. Acapecitabine; B5-fluorouracil, leucovorin; CAPOX capecitabine,
oxaliplatin; CAPOX-B capecitabine, oxaliplatin, bevacizumab; CRS-HIPEC cytoreductive surgery with hyperthermic intraperitoneal chemotherapy; CT
computed tomography; FOLFIRI 5-fluorouracil, leucovorin, irinotecan; FOLFIRI-B 5-fluorouracil, leucovorin, irinotecan, bevacizumab; FOLFOX 5-
fluorouracil, leucovorin, oxaliplatin; FOLFOX-B 5-fluorouracil, leucovorin, oxaliplatin, bevacizumab
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two-sided log-rank test at p < 0.05. The primary study
hypothesis may be modified when new insights or new
guiding literature become available.
Recruitment
Potential study candidates are enrolled by dedicated spe-
cialised physicians in high-volume study centres. Accrual
is considered feasible when the first 80 patients are en-
rolled within one year after the start of accrual in the
last study centre, since this ensures completion of the
phase III study within a maximum of four years.
Assignment of interventions
Eligible patients who are enrolled by physicians in study
centres are centrally randomised and assigned to interven-
tions by the coordinating investigators (KPR and CB) in a
1:1 ratio by using randomisation software (ALEA, For-
msVision, Abcoude, Netherlands) with minimisation
stratified by a PCI of 0–10 or 11–20, synchronous or
metachronous PM, previous systemic therapy for colorec-
tal cancer, and HIPEC with oxaliplatin or mitomycin C.
Data collection
Questionnaires are collected by the coordinating inves-
tigators. All other baseline and outcome data are col-
lected and entered in the central study database
(TRIAS, Netherlands Comprehensive Cancer Organ-
isation [IKNL], Utrecht, Netherlands) with electronic
case report forms by independent, qualified, and
trained local data managers of independent in-hospital
trial departments (two study centres) or IKNL
(all other centres).
Data management
Data coding, security, and storage, including processes
to promote data quality, are performed by an inde-
pendent, qualified, and trained central data manager
of IKNL (JMB).
Statistical methods
Overall survival, progression-free survival, health-related
quality of life, and costs are analysed in all randomised
patients (intention-to-treat population). Radiological re-
sponse and systemic therapy related toxicity are analysed
in all patients who received at least one dose of peri-
operative systemic therapy (systemically treated popula-
tion). Surgical characteristics, histopathological response,
postoperative morbidity, and disease-free survival are
analysed in all patients who receive CRS-HIPEC (oper-
ated population). Categorical variables are expressed as n
(%). Continuous variables are expressed as mean (standard
deviation) or median (range) where appropriate. All tests
are two-sided and p < 0.05 is considered statistically sig-
nificant in all analyses.
The median follow-up period is calculated by using
the reverse Kaplan-Meier method. Kaplan-Meier
curves of time-to-event variables are compared be-
tween both arms by using the two-sided log-rank test.
Unadjusted and confounder-adjusted hazard ratios
with two-sided 95% confidence intervals are estimated
by using Cox proportional hazards models. Subgroup
analyses are performed with stratification for relevant
baseline characteristics that will be defined before the
final dataset is locked. Data on patients who are
event-free are censored on the date the patient is last
seen. Categorical baseline characteristics and categor-
ical outcomes are compared between both arms by
using the Chi-square test or the Fisher’s exact test
where appropriate. Continuous baseline characteristics and
outcomes are compared between both arms by using the
Mann-Whitney U test or the student’s t test where appro-
priate. Health-related quality of life is graphically presented
across all time points and compared between both arms by
using a repeated measures analysis of variance. Incremental
cost-effectiveness and cost-utility ratios are calculated for
the extra costs per additional patient alive and the extra
costs per additional quality adjusted life year, respectively.
Non-parametric bootstrapping, drawing samples of the
same size as the original samples and with replacement, is
applied to generate 95% confidence intervals for (differ-
ences in) costs and health outcomes. Cost-effectiveness
planes are displayed and cost-effectiveness acceptability
curves are drawn for willingness-to-pay values up to
€100.000,-.
Data monitoring committee
The data monitoring committee (DMC) consists of a
surgeon (CV), a medical oncologist (HWML), and a stat-
istician (AHZ), who are all independent from the spon-
sor and competing interests. Their role is to monitor
patient safety through three interim analyses after 80
(phase II study), 160, and 240 patients complete their
study treatment. Relevant data are made available to the
DMC by the central data manager and the study statisti-
cian (MGAD). The study is terminated after the first in-
terim analysis if less than 50% of the patients in the
experimental arm undergo complete CRS-HIPEC or if
the percentage of patients with major postoperative
morbidity (Clavien-Dindo grade ≥ 3) is ≥20% higher in
the experimental arm compared to the control arm.
After each interim analysis, the DMC reports their ad-
vice on study continuation to the study steering commit-
tee (PHJH, CJAP, PJT, IHJTH). The study steering
committee submits these reports to the ethics commit-
tee and notifies the ethics committee when (part of) the
advice of the DMC is not followed. The study steering
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committee makes the final decision to terminate or con-
tinue the study.
Harms
Physicians of study centres report all serious adverse
events (SAEs) or suspected unexpected serious adverse
reactions (SUSARs) to the coordinating investigators
within 24 h. The coordinating investigators report SAEs/
SUSARs through the web portal ToetsingOnline to the
ethics committee within seven days of first knowledge
for lethal or life-threatening SAEs/SUSARs, and within
fifteen days for other SAEs/SUSARs. The time window
for reporting SAEs/SUSARs is from randomisation to
three months after CRS-HIPEC or one month after the
last administration of systemic therapy. The clinical
course of all SAEs/SUSARs is followed until resolution,
stabilisation, or determination that study participation is
not the underlying cause of the SAE/SUSAR.
Auditing
The study is audited by independent qualified monitors
of IKNL as a study with a moderate risk according to
the brochure ‘Kwaliteitsborging mensgebonden onder-
zoek 2.0’ by the Dutch Federation of University Medical
Centres. During the phase II study, each study centre is
audited twice, with a focus on essential study docu-
ments, informed consent procedures, eligibility criteria,
source data verification, and SAEs/SUSARs. Frequency
and procedures for auditing of the phase III study are
not specified and depend on auditing reports of the
phase II study.
Research ethics approval
This study is approved by the Dutch competent au-
thority (CCMO, The Hague, Netherlands), a central
ethics committee (MEC-U, Nieuwegein, Netherlands),
and the institutional review boards (IRBs) of all study
centres. The study will be submitted to the IRBs of
the satellite centres once the accrual of the phase II
study is completed.
Protocol amendments
Important protocol modifications are communicated to
all investigators, the Dutch competent authority, the
central ethics committee, the IRBs of all study centres,
and trial registries.
Consent and assent
Written informed consent is obtained by physicians at
the outpatient clinics of the study centres. Patients are
given the possibility to give separate permission for re-
ceiving questionnaires and for participation in blood and
tissue collection for translational research.
Confidentiality
Personal information about potential and enrolled pa-
tients is collected, shared, and maintained according
to the Dutch law (Wet Bescherming Persoonsgege-
vens) to protect confidentiality before, during, and
after the study.
Declaration of interests
The investigators declare no competing interests.
Hoffman-La Roche awarded an unrestricted scientific
grant for this investigator-initiated study, but has no
role in the design of the study, in the collection, ana-
lysis, and interpretation of data, and in writing the
manuscripts.
Access to data
The central data manager, study statistician, coordinat-
ing investigators, and the study steering committee have
access to the final datasets, without any contractual
agreements that limit such access.
Ancillary and post-study care
This study has no provisions for ancillary and post-study
care. The sponsor (Catharina Hospital, Eindhoven,
Netherlands) is insured to provide cover for those who
suffer harm from study participation.
Dissemination policy
Results of the phase II and phase III studies are person-
ally communicated to participating patients. Results are
communicated to healthcare professionals through pub-
lication in peer-reviewed medical journals without any
publication restrictions. The manuscripts are written by
the coordinating investigators, the study statistician, the
study steering committee, and a professional English
writer. Authorship is granted to the central data
manager, the DMC, and investigators who analyse sec-
ondary outcomes (e.g. radiological or histopathological
response). Authorship for physicians of study centres is
granted based on the number of enrolled patients: one
author for five (phase II) and twenty (phase III) patients,
and an additional author for each three (phase II) and
fifteen (phase III) additional patients. All other
physicians and other healthcare professionals who con-
tributed to the study are listed as collaborators. The full
protocol and Dutch informed consent forms are publicly
accessible [92]. Participant-level datasets and statistical
codes will become available upon reasonable request.
Discussion
This is the first randomised study that prospectively com-
pares oncological outcomes of perioperative systemic ther-
apy and CRS-HIPEC with upfront CRS-HIPEC alone in
patients with isolated resectable colorectal PM. Results of
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this study will reveal whether addition of perioperative
systemic therapy to CRS-HIPEC has an intention-to-treat
benefit for these patients.
To the knowledge of the authors, there are no on-
going first-line or (neo)adjuvant randomised studies
in metastatic colorectal cancer that could lead to
modifications of the perioperative systemic therapy
within the study protocol on the short term. How-
ever, there are two ongoing single arm phase II stud-
ies that investigate perioperative systemic therapy for
patients with resectable colorectal PM who qualify
for CRS-HIPEC. The BEV-IP study (NCT02399410)
administers perioperative combination chemotherapy
with bevacizumab to 45 patients with postoperative
morbidity as primary outcome [93]. The CARCINO-
SIS study (NCT02591667) administers neoadjuvant
triplet chemotherapy with bevacizumab to 35 patients
with histopathological response as primary outcome.
Results of these studies are actively followed to as-
sess whether the study protocol needs to be modi-
fied. Furthermore, four studies randomise patients
with colorectal peritoneal metastases after complete
cytoreductive surgery: one to HIPEC with oxaliplatin
or no HIPEC (PRODIGE7, NCT00769405), one to
concentration-based or BSA-based HIPEC with oxali-
platin (COBOX, NCT03028155), one to HIPEC with
mitomycin C or melphalan (NCT03073694), and one
to HIPEC with mitomycin C or early postoperative
intraperitoneal chemotherapy with leucovorin/floxuri-
dine (ICARUS, NCT01815359). Results of these stud-
ies are closely monitored to assess whether HIPEC
within the study protocol needs to be modified or
omitted.
The study protocol has several potential limitations.
Determination of resectable colorectal PM prior to
enrolment could be difficult, since both abdominal
CT and diagnostic laparoscopy tend to underestimate
the PCI [94–97]. Moreover, the diagnostic laparos-
copy/laparotomy prior to enrolment may also be per-
formed in less experienced referring centres. As a
result, patients with unresectable disease may be en-
rolled in the study. However, it is assumed that strati-
fication by PCI equally divides these patients between
both arms. Furthermore, when the diagnostic laparos-
copy/laparotomy is performed in a referring centre,
the PCI should be accurately scored and documented
before patients can be enrolled [76]. In the future,
diffusion-weighted MRI (DW-MRI) may be added to
the standard preoperative work-up given its promising
preliminary results in detecting resectable colorectal
PM [98]. Enrolment of patients with radiologically
non-measurable disease could impede response assess-
ment to neoadjuvant systemic therapy [99]. However,
since non-measurable colorectal PM are frequently
observed in clinical practice, especially in patients with a
low PCI or metachronous PM, the investigators decided
to allow enrolment of these patients in order to create a
representative study population. Enrolment is also allowed
for patients who are referred to a study centre after a
macroscopically complete resection of colorectal PM in a
referring centre, since it is assumed that microscopic
(and often macroscopic) colorectal PM are still present.
The study protocol has potential strengths. The ac-
crual is expected to be feasible, since potential study
candidates are seen by dedicated specialised physicians
in all Dutch high-volume centres. Moreover, patients
with isolated resectable colorectal PM do not qualify for
any other multicentre randomised study in the
Netherlands. The phase II-III approach allows for ad-
equate monitoring of the feasibility and safety of peri-
operative systemic therapy in this setting. Extensive
assessment of health-related quality of life and costs
could help to standardise the treatment paradigm in the
era of value-based medicine, whereas translational side
studies may open new avenues for research in the era of
increasing insights in the different molecular subtypes of
colorectal cancer.
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